Clinical trials: Colorectal Diseases
Metastatic Colorectal Cancer
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
- Trial name
- NCT01437618
- Testing
- FOLFOXIRI plus bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
- Trial name
- CARTIER (NCT03711110)
- Testing
- Intensive cardiovascular monitoring, No intervention
- Where
- 14 sites in Spain
- Volunteers
- 514 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Crohn's Disease, Inflammatory Bowel Disease
A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques
Postoperative pain can pose significant challenges in the postoperative recovery of patients undergoing major colorectal surgery. Traditionally, opioids have played an important role in treating postoperative pain.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, Postoperative Pain
- Trial name
- NCT02538679
- Testing
- US TAP Bupivacaine/Epinephrine, Lap TAP Bupivacaine/Epinephrine
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Gastrointestinal Cancer
Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy
The goal of this study is to learn more about the symptoms that may occur in patients with GI cancer. The types of GI cancer being studied are cancers of the stomach, liver, pancreas, colon, and rectum.
- Trial name
- NCT00849979
- Testing
- Questionnaire, Interview
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the…
- Trial name
- NCT03516708
- Testing
- Epacadostat, Short-course radiation therapy, CAPOX chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, Colorectal Cancer
Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers
The aim of the project is to study the role of minimally invasive imaging methods, such as magnification endoscopy with narrow-band imaging (M-NBI) combined with confocal laser endomicroscopy (CLE), in correlation with…
- Conditions
- Gastric Cancer, Colorectal Cancer, Gastrointestinal Neoplasms
- Trial name
- IM-ANG (NCT02672774)
- Testing
- Magnification endoscopy with narrow band imaging, Probe based confocal laser endomicroscopy
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- University of Medicine and Pharmacy Craiova
Colorectal Neoplasms
Evaluation of Some Risk Factors Associated With Colorectal Cancer
1. Evaluation of some risk factors (e.g. smoking, heavy metal exposure, and organophosphorus exposure) on CRC. 2. Estimation of KRAS and BRAF genes mutations associated with CRC. 3.
- Trial name
- NCT05170360
- Testing
- Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:
- Volunteers
- 100 people
- Sponsor
- Assiut University
Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation. However, preoperative radiation cause kinds of adverse events, some were irreversible. And the survival benefit was not obvious.
- Trial name
- FORTUNE (NCT02217020)
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
This phase I trial studies the side effects and the best dose of irinotecan hydrochloride, based on a genetic test, when given in combination with fluorouracil, leucovorin calcium, and cetuximab as first-line therapy in treating…
- Trial name
- NCT02573220
- Testing
- Cetuximab, Fluorouracil, Irinotecan Hydrochloride
- Where
- Italy
- Sponsor
- University of Chicago
Rectal Cancer
ArtiSential® for Rectal Cancer Surgery
This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for…
- Trial name
- NCT06236282
- Testing
- ArtiSential®
- Where
- South Korea
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Circulating Markers, Metastatic Colorectal Cancer
Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer
The chemotherapy monitoring is currently based on radiological (RECIST 1.1 guideline) and clinical evaluation every 3 months. Circulating markers as Carcino Embryonic Antigen (CEA), circulating tumour DNA and total cell free DNA…
- Trial name
- COCA-MACS (NCT02872779)
- Testing
- Blood sampling for free mutant DNA analysis
- Where
- France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Rouen
Colorectal Cancer (CRC)
A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer
This study aims to evaluate the safety, tolerability, and efficacy of pirfenidone and PD-1 monoclonal antibody combined with or without hypofractionated radiotherapy in the treatment of advanced refractory pMMR/MSS colorectal…
- Trial name
- NCT07644286
- Testing
- Pirfenidone in combination with a PD-1 inhibitor, hypofractionated radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Tao Zhang
Quality of Life
A Real-world Clinical Study of Kapok Initiative
This study is a prospective and effective research study. The aim is to assess the difference in the quality of life of the family members of patients with colorectal cancer after application of follow-up disease management using…
- Trial name
- NCT04735991
- Testing
- Kapok Initiative
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Colon Neoplasm
Calculating of Correlations Between ADR, PDR, MAP
The aim of our study is to compare MAP (mean adenoma per colonoscopy) with ADR (adenoma detection rate) and PDR (polyp detection rate) of all colonoscopists in our department
- Trial name
- NCT03723720
- Testing
- Colonoscopy
- Where
- Czechia
- Volunteers
- 6,925 people
- Sponsor
- Hospital Frydek-Mistek
Colorectal Neoplasms, Metastatic Disease
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
- Trial name
- REFRAME (NCT01875380)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Immunotherapy, Gastric Cancer
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
immunotherapy，gastric cancer，rectal cancer，biomark
- Conditions
- Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect
- Trial name
- NCT05515796
- Testing
- Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Rectal Neoplasms
Study for Wait and Watch Suitable in Rectal Cancer
One of the standard treatment options offered to patients of locally advanced rectal cancer is neoadjuvant (treatment given before surgery) radiotherapy \& chemotherapy followed by surgery.
- Trial name
- ARROW (NCT06252142)
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Centre
Metastatic Colorectal Cancer
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy.
- Trial name
- SPECTRA (NCT00958386)
- Testing
- Panitumumab+irinotecan
- Where
- Spain
- Volunteers
- 61 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Pseudomyxoma Peritonei, Colorectal Cancer
HIPEC Using High Intra-abdominal Pressure
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising therapy for peritoneal carcinomatosis (PC) of various origins.
- Trial name
- HIPEC-IAP (NCT02949791)
- Testing
- Cytoreductive surgery, Low Intra abdominal pressure HIPEC, High Intra abdominal pressure HIPEC
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.